- Home
- JOF vs MREO Comparison
JOF vs MREO Comparison
Compare JOF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOF
- MREO
- Stock Information
- Founded
- JOF 1990
- MREO 2015
- Country
- JOF Japan
- MREO United Kingdom
- Employees
- JOF N/A
- MREO N/A
- Industry
- JOF Trusts Except Educational Religious and Charitable
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- JOF Finance
- MREO Health Care
- Exchange
- JOF Nasdaq
- MREO Nasdaq
- Market Cap
- JOF 295.0M
- MREO 326.1M
- IPO Year
- JOF N/A
- MREO N/A
- Fundamental
- Price
- JOF N/A
- MREO $1.97
- Analyst Decision
- JOF
- MREO Strong Buy
- Analyst Count
- JOF 0
- MREO 5
- Target Price
- JOF N/A
- MREO $7.40
- AVG Volume (30 Days)
- JOF 43.9K
- MREO 1.3M
- Earning Date
- JOF 01-01-0001
- MREO 11-11-2025
- Dividend Yield
- JOF 3.33%
- MREO N/A
- EPS Growth
- JOF N/A
- MREO N/A
- EPS
- JOF N/A
- MREO N/A
- Revenue
- JOF N/A
- MREO $500,000.00
- Revenue This Year
- JOF N/A
- MREO N/A
- Revenue Next Year
- JOF N/A
- MREO $72.16
- P/E Ratio
- JOF N/A
- MREO N/A
- Revenue Growth
- JOF N/A
- MREO N/A
- 52 Week Low
- JOF $6.64
- MREO $1.47
- 52 Week High
- JOF $8.04
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- JOF 52.09
- MREO 56.96
- Support Level
- JOF $10.51
- MREO $1.92
- Resistance Level
- JOF $11.00
- MREO $2.12
- Average True Range (ATR)
- JOF 0.14
- MREO 0.11
- MACD
- JOF -0.02
- MREO 0.01
- Stochastic Oscillator
- JOF 24.49
- MREO 60.41
About JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).